Through R&D innovations and collaborative partnerships, we're investing in cutting-edge research to open the door for new assay development that Power the Moments That Matter.
See our schedule below for information on our symposia, product theater, and posters.
Advancing the future of neurological disease diagnostics globally with innovative technologies and assays that will deliver accurate and affordable testing solutions at scale.
We are partnering with leading clinical researchers to create a discovery ecosystem to unlock the full potential of the latest scientific advances—developing a robust portfolio of highly sensitive assays that can ultimately be used for neurodegenerative disease diagnostics to enable earlier disease detection.
Our goal? To change the paradigm of patient care with less invasive assays that deliver more insights into neurodegenerative diseases.
 |
 |
We’re pushing boundaries with next-generation technologies that improve workflow and drive confidence in results.
Leveraging our IVD expertise, we’re innovating best-in-class, highly sensitive blood-based biomarker assays to improve disease research—ultimately improving testing accessibility and enhancing clinical decision making.
| Assays for Research Use Only | IFU | Information Bulletin |
| p-Tau217 | Link | Link |
| GFAP | Link | Link |
| NfL | Link | Link |
| APOE ε4 | Link | Link |
| Research Use Only Assays in Development | ||
| ß-AmyIoid 1-42 | ||
| BD Tau | ||
| MTBR-Tau | ||
| TDP-43 | ||
| Assay has been granted BDD from the U.S. FDA | ||
| p-Tau217/ß-AmyIoid 1-42 Plasma Ratio* | ||
*IVD Assay in Development. Not currently for use in diagnostic procedures.
For Research Use Only.
Title: Advances in Blood-Based Biomarkers for Alzheimer's Disease: Integrating the ATN Framework Amidst Disease Heterogeneity
Date: Sunday, July 27, 2025
Time: 12:30 – 1:45 pm
Lunch will be served
Location: Frontenac Ballroom, Westin Harbour Castle
Keynote Speakers: Coming Soon
Symposium Highlights: The Amyloid, Tau, Neurodegeneration (ATN) biomarker framework is shifting our understanding of the progression of Alzheimer’s disease. Concurrently, advances in blood-based biomarkers (BBBM) offer a promising and less invasive future to currently available PET and CSF testing. We will explore integration of BBBMs within the ATN diagnostic framework and address their potential and limitations in capturing the multifaceted nature of Alzheimer’s disease.
To Register for our Symposia Click Here
Sponsored by Biogen, Beckman Coulter Diagnostics, and Fujirebio
Title: Clinical Utility of the Plasma p-tau217/Aβ42 Ratio for Early Detection and Monitoring of Alzheimer’s Disease
Date: Tuesday, July 29, 2025
Time: 6:15 – 7:45 am
Breakfast will be served
Location: Frontenac Ballroom, Westin Harbour Castle
Keynote Speakers: Coming Soon
Symposium Highlights: Blood-based testing is minimally invasive, cost-effective, and scalable, making it ideal for use in primary care or memory clinics, but accuracy is paramount. Join us as we discuss the clinical utility of the plasma p-Tau217/Aβ42 ratio and how this powerful biomarker could be used for early detection and monitoring of Alzheimer’s disease (AD).
To Register for our Symposia Click Here
Sponsored by Danaher and Beckman Coulter
Join us at the product theater
APOE ε4 is the strongest genetic risk factor for developing Alzheimer’s disease—and carrying the APOE ε4 allele increases the risk of developing ARIA in response to disease-modifying therapies. Two RUO assays for identifying APOE ε4 zygosity will be discussed.
Speaker: Coming Soon
Date: Tuesday, July 29, 2025
Time: 10:35 - 11:05 am.
Location: Product Theater Stage Booth #928 (Center of the 900 aisle on the exhibit floor)
| Monday, July 28, 2025
Poster # 103328* High-throughput, fully automated immunoassay for detecting zygosity of apolipoprotein ε4 (APOE ε4) in plasma EDTA |
Tuesday, July 29, 2025 Performance of the Beckman Coulter
prototype plasma p-Tau217 and p-Tau217/Aβ42 ratio assays in a cohort of individuals with cognitive impairment |
|
Wednesday, July 30, 2025 New High-throughput, Fully Automated BD-Tau Immunoassay |
Wednesday July 30, 2025 New High-Throughput Fully Automated Immunoassay for Plasma Neurofilament Light Chain |
*Presenters will be at posters during breaks and lunch
Learn more. Check out these articles:
Thank you for your request. A Beckman Coulter representative will contact you shortly.
English
